Tim Schlidt is the co-founder of psychedelic-focused VC fund Palo Santo. He is one of the leading voices pushing for the development of psychedelic-backed mental health therapies and has deployed over $25 million into 20 companies. Schlidt is also pushing for the FDA approval of psychedelic-assisted therapies to make them more accessible, affordable, and safe for patients suffering from treatment-resistant depression.
In this episode of Hone In, host Saad Alam sat down with him to talk about what goes down during a therapeutic trip, ongoing clinical trials for psychedelics including ketamine, MDMA, and psilocybin, and the growing acceptance of psychedelics in mental health care.
This conversation is an absolute game-changer. It covers both scientific inquiry and personal experiences, offering you a comprehensive understanding of the profound potential of therapeutic psychedelics.
- How psychedelics literally rewire your brain by promoting neuroplasticity
- The anti-inflammatory and longevity benefits of psychedelics
- How MDMA and psilocybin are being used to treat PTSD and treatment-resistant depression
- How Tim’s own experience with severe depression led him to invest in companies researching psychedelics
- The mental health benefits of “ego death”
IN THIS EPISODE YOU’LL LEARN:
- The difference between a psychedelic microdose and a macrodose
- Why psychedelics could yield better results than SSRIs
- When to expect FDA approval of psychedelic therapies
- How much psychedelic-assisted therapy costs
- And more